Jump to content

Pathkind Labs

From Wikipedia, the free encyclopedia
Pathkind Labs
Company typePrivate limited company
IndustryHealthcare
Founded2016
FounderSanjeev Vashishta
Headquarters,
India
Number of locations
70 diagnostic labs and 2000+ collection centers
Area served
India
Key people
Sanjeev Vashishta
ServicesRadiology and pathology diagnostic services
Websitewww.pathkindlabs.com

Pathkind Labs is an Indian service provider of diagnostic and related healthcare tests. It was founded in 2016. The business has 70 diagnostic labs and over 2000 centers in India[1] and is accredited with the NABL and NABH.[2][3]

History

[edit]

Pathkind Labs was set up in 2016. It is promoted by diagnostic industry veteran Sanjeev Vashishta and the promoters of Mankind Pharma.[4]

Pathkind Diagnostics began its operations in August 2017 and currently operates in 20+ states in India. The company has a network of over 70 labs and more than 2000+ collection centers. Pathkind Labs was authorized by the Indian Council of Medical Research and various state governments to undertake COVID-19 testing.[5] In response to the COVID-19 pandemic, Pathkind established 10 labs in various cities that provided Covid RT-PCR and other related tests.[1]

In 2022, India Business Excellence Fund IV, a fund managed by Motilal Oswal Private Equity, invested up to 194.4 crore in Pathkind Diagnostics. The investment contributed to the company's continued development as a provider of pathology services in India.[2]

In November 2021, it opened a pathology lab in Nagpur, Maharashtra. This expansion is part of the company's plan to grow its presence in the western and central regions of India, including Maharashtra. It was inaugurated by Nitin Gadkari, the Minister of Road Transport and Highways of India.[6]

On World Diabetes Day 2022, Pathkind Labs organized Diabetes Camps in more than 2,000 centers across India to raise awareness about diabetes. The camps offered free sugar panel tests with a nominal registration fee. It was named in the India Book of Records.[7] The lab was awarded the Businessworld Healthcare Excellence Award 2022 for Excellence in Pathology – Impact in Tier 2 & 3 category by Businessworld magazine in September 2022.[8]

In January 2023, Pathkind Labs and Roche Diagnostics jointly introduced the cardiac biomarker NTProBNP for the detection of heart failure in patients.[9]

References

[edit]
  1. ^ a b "Union Minister Nitin Gadkari inaugurates a new state-of-the-art pathology lab in Nagpur". Nagpur Today. October 28, 2021.
  2. ^ a b Pilla, Vishwanath (May 20, 2022). "Motilal Oswal Private Equity invests RS 194.4 crore in Pathkind Diagnostics". The Economic Times.
  3. ^ "Diagnostic Centre". Nabh.co.
  4. ^ Mani, Veena (March 24, 2017). "Mankind Pharma set to foray into diagnostics with Pathkind".
  5. ^ "ICMR releases list of private labs for coronavirus tests". Siasat. April 22, 2020.
  6. ^ "Pathkind Diagnostics launches new lab in Maharashtra". Express Healthcare. Indian Express. November 2, 2021.
  7. ^ "Pathkind Labs Secures A Spot In India Book Of Records". Business World. December 2, 2022.
  8. ^ Tyagi, Shivam (September 10, 2022). "Honouring The Excellence In Healthcare". Businessworld.
  9. ^ "Pathkind Labs, Roche Diagnostics partner to release cardiac biomarker". The Economic Times. January 6, 2023.
[edit]